Journals / Türk Nefroloji Diyaliz ve Transplantasyon Dergisi / 2011 / Cilt: 20 - Sayı: 1

Development of reversible posterior leukoencephalopathy syndrome after cyclophosphamide treatment in a patient with lupus nephritis

Bir lupus nefriti hastasında siklofosfamid tedavisi sonrası gelişen geri dönüşümlü posterior lökoensefalopati sendromu

Pages
104–107
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We present a case of lupus nephritis in which reversible posterior leucoencephalopathy syndrome developed after intravenous cyclophosphamide administration and recovered spontaneously by symptomatic treatment in this article.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Renal involvement in systemic lupus erythematosus is a frequent and serious complication that significantly increases morbidity and mortality.
📊
Key Findings & Data:Despite all studies and usage of new drugs, treatment of lupus nephritis continues to be a problem.
💡
Conclusion & Impact:We present a case of lupus nephritis in which reversible posterior leucoencephalopathy syndrome developed after intravenous cyclophosphamide administration and recovered spontaneously by symptomatic treatment in this article.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Renal involvement in systemic lupus erythematosus is a frequent and serious complication that significantly increases morbidity and mortality. Despite all studies and usage of new drugs, treatment of lupus nephritis continues to be a problem. Diffuse proliferative lupus nephritis has a poor prognosis and aggressive treatment must be undertaken. Cyclophosphamide is commonly used in treatment despite its side effects. Reversible posterior leucoencephalopathy syndrome is a clinico-radiological syndrome manifested by blood pressure elevation, headache, visual disturbances, confusion, seizures and sometimes focal neurological signs that can develop due to usage of cytotoxic drugs. We present a case of lupus nephritis in which reversible posterior leucoencephalopathy syndrome developed after intravenous cyclophosphamide administration and recovered spontaneously by symptomatic treatment in this article.

Özet

Sistemik lupus eritematozus'ta böbrek tutulumu, morbidite ve mortaliteyi anlamlı derecede arttıran sık ve ciddi bir komplikasyondur. Lupus nefritinin tedavisi tüm çalışmalara ve yeni ilaçların kullanılmasına rağmen önemli bir problem olmaya devam etmektedir. Diffüz proliferatif lupus nefriti en kötü prognoza sahiptir ve agresif tedavi edilmesi gerekmektedir. Tedavide istenmeyen yan etkileri olmasına rağmen siklofosfamid yaygın olarak kullanılmaktadır. Reversibl (geri dönüşümlü) posterior lökoensefalopati sendromu sitotoksik ilaçların kullanılmasına bağlı olarak ortaya çıkabilen, klinik olarak ani kan basıncı yüksekliği ile birlikte baş ağrısı, görme bozuklukları, konfüzyon ve nöbetler ile karakterize, bazen fokal nörolojik bulguların da eşlik ettiği bir klinikoradyolojik sendromdur. Yazımızda lupus nefriti tanısı alan, damardan siklofosfamid uygulaması sonrası geri dönüşümlü posterior lökoensefalopati sendromu gelişen ve semptomatik tedavi ile kendiliğinden düzelen bir olgu sunulacaktır.

🔖

Cite This Article

DEĞİRMENCİ, E., GÜÇLÜ, A., YILDIZ, S., ÇOBANKARA, V., TOPALOĞLU, M., ERÜRKER, M., YALÇIN, N., KIROĞLU, Y. (2022). Development of reversible posterior leukoencephalopathy syndrome after cyclophosphamide treatment in a patient with lupus nephritis. Türk Nefroloji Diyaliz ve Transplantasyon Dergisi, Cilt: 20 - Sayı: 1, 104–107. https://ajindex.com/articles/636448

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. D’Cruz DP, Khamashta MA, Hughes GR: Systemic lupus erythematosus. Lancet 2007; 369: 587-596 2. Austin HA, Balow JE: Treatment of lupus nephritis. Semin Nephrol 2000; 20:265-276 3. Petri M: Cyclophosphamide: New approaches for systemic lupus erythematosus. Lupus 2004; 13: 366-371 4. Garg RK: Posterior leukoencephalopathy syndrome. Postgrad Med J 2001; 77: 24-28 5. Min L, Zwerling J, Ocava LC, Chen IH, Putterman C: Reversible posterior leukoencephalopathy in connective tissue diseases. Semin Arthritis Rheum 2006; 35: 388-395 6. Hughes RL: Cyclosporine-related central nervous system toxicity in cardiac transplantation. N Engl J Med 1990; 323: 420-421 7. Kemper MJ, Spartà G, Laube GF, Miozzari M, Neuhaus TJ: Neuropsychologic side-effects of tacrolimus in pediatric renal transplantation. Clin Transplant 2003; 17: 130-134 8. Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, Pessin MS, Lamy C, Mas JL, Caplan LR: A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996; 334: 494-500 9. Casey SO, Sampaio RC, Michel E, Truwit CL: Posterior reversible encephalopathy syndrome utility of FLAIR imaging in the detection of cortical and subcortical lesions. AJNR Am J Neuroradiol 2000; 21: 1119-1206 10. Obeid T, Shami A, Karsou S: The role of seizures in reversible posterior leukoencephalopathy. Seizure 2004; 13: 277-281 11. Muscal E, Brey RL: Neurologic manifestations of systemic lupus erythematosus in children and adults. Neurol Clin 2010; 28: 61-73 12. Sibley JT, Olszynski WP, Decoteau WE, Sundaram MB: The incidence and prognosis of central nervous system disease in systemic lupus erythematosus. J Rheumatol 1992; 19: 47-52 13. Sibbitt WL Jr, Sibbitt RR, Griffey RH, Eckel C, Bankhurst AD: Magnetic resonance and computed tomographic imaging in the evaluation of acute neuropsychiatric disease in systemic lupus erythematosus. Ann Rheum Dis 1989; 48: 1014-1022